Literature DB >> 18685404

Dyspnea in interstitial lung disease.

Harold R Collard1, Steven Z Pantilat.   

Abstract

PURPOSE OF REVIEW: Dyspnea is a common complication of interstitial lung disease, yet little is known about its cause and effective management. This review attempts to summarize the current state of the art in this area. RECENT
FINDINGS: Dyspnea is a near-universal finding in people with interstitial lung disease, predominantly due to neuromechanical abnormalities. Several well studied metrics exist for the measurement of dyspnea in this population, and its severity has been linked to quality of life and survival. The management of dyspnea in interstitial lung disease remains a challenge, with no proven pharmacological options. Pulmonary rehabilitation shows therapeutic promise, and aggressive treatment of physical and psychiatric comorbidities is important.
SUMMARY: Dyspnea remains a common and difficult to treat symptom for people with interstitial lung disease. More research is sorely needed.

Entities:  

Mesh:

Year:  2008        PMID: 18685404     DOI: 10.1097/SPC.0b013e3282ff6336

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  12 in total

1.  Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease.

Authors:  Jeffrey J Swigris; Janelle Yorke; David B Sprunger; Christopher Swearingen; Theodore Pincus; Roland M du Bois; Kevin K Brown; Aryeh Fischer
Journal:  Respir Med       Date:  2010-05-14       Impact factor: 3.415

2.  Respiratory muscles in interstitial lung disease: poorly explored and poorly understood.

Authors:  Bruno Guedes Baldi; João Marcos Salge
Journal:  J Bras Pneumol       Date:  2016-04       Impact factor: 2.624

3.  Does nebulized fentanyl relieve dyspnea during exercise in healthy man?

Authors:  Houssam G Kotrach; Jean Bourbeau; Dennis Jensen
Journal:  J Appl Physiol (1985)       Date:  2015-03-12

4.  Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease.

Authors:  Randall E Keyser; Joshua G Woolstenhulme; Lisa M K Chin; Steven D Nathan; Nargues A Weir; Gerilynn Connors; Bart Drinkard; James Lamberti; Leighton Chan
Journal:  J Cardiopulm Rehabil Prev       Date:  2015 Jan-Feb       Impact factor: 2.081

5.  The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis.

Authors:  Ivana V Yang; Leah G Luna; Jennifer Cotter; Janet Talbert; Sonia M Leach; Raven Kidd; Julia Turner; Nathan Kummer; Dolly Kervitsky; Kevin K Brown; Kathy Boon; Marvin I Schwarz; David A Schwartz; Mark P Steele
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

6.  Are physicians in primary health care able to recognize pulmonary fibrosis?

Authors:  Minna Purokivi; Ulla Hodgson; Marjukka Myllärniemi; Eija-Riitta Salomaa; Riitta Kaarteenaho
Journal:  Eur Clin Respir J       Date:  2017-02-20

7.  Indications and patterns of use of benzodiazepines and opioids in severe interstitial lung disease: a population-based longitudinal study.

Authors:  Jenny Genberg; Joanna M Davies; Zainab Ahmadi; David Currow; Miriam J Johnson; Hanan Tanash; Sabrina Bajwah; Magnus Ekström
Journal:  ERJ Open Res       Date:  2021-02-01

8.  The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial.

Authors:  Leona Dowman; Christine F McDonald; Catherine Hill; Annemarie Lee; Kathryn Barker; Claire Boote; Ian Glaspole; Nicole Goh; Annemarie Southcott; Angela Burge; Rebecca Ndongo; Alicia Martin; Anne E Holland
Journal:  BMC Pulm Med       Date:  2013-02-01       Impact factor: 3.317

9.  Function of the transforming growth factor-β1/c-Jun N-terminal kinase signaling pathway in the action of thalidomide on a rat model of pulmonary fibrosis.

Authors:  Xuejun Liu; Li Qian; Haoyu Nan; Miao Cui; Xiaoyan Hao; Yufeng DU
Journal:  Exp Ther Med       Date:  2013-12-19       Impact factor: 2.447

10.  Low expression of long noncoding RNA CDKN2B-AS1 in patients with idiopathic pulmonary fibrosis predicts lung cancer by regulating the p53-signaling pathway.

Authors:  Yufeng Du; Xiaoyan Hao; Xuejun Liu
Journal:  Oncol Lett       Date:  2018-01-31       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.